Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.
Company profile
Ticker
VXGN
Exchange
CEO
Lori F. Rafield
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Vaxgen Inc
SEC CIK
Corporate docs
IRS number
943236309
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
8 Dec 20
10-Q
2016 Q1
Quarterly report
29 Apr 16
8-K
Diadexus, Inc. Reports First Quarter 2016 Financial Results
29 Apr 16
8-K
Diadexus, Inc. Previews First Quarter 2016 Financial Performance and Provides Business Update
18 Apr 16
8-K
Changes in Registrant's Certifying Accountant
1 Apr 16
10-K
2015 FY
Annual report
29 Mar 16
8-K
Updated - Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
29 Mar 16
8-K
Departure of Directors or Certain Officers
18 Mar 16
CT ORDER
Confidential treatment order
5 Jan 16
10-Q
2015 Q3
Quarterly report
30 Oct 15
Latest ownership filings
SC 13G/A
Diadexus, Inc.
9 Aug 18
SC 13G/A
Diadexus, Inc.
13 Feb 18
SC 13G
Diadexus, Inc.
13 Feb 17
SC 13D
Diadexus, Inc.
28 Mar 16
SC 13G/A
Diadexus, Inc.
9 Feb 16
4
Karen Drexler
16 Jul 15
4
John T Curnutte
16 Jul 15
4
John J Sperzel III
16 Jul 15
4
JAMES R SULAT
16 Jul 15
4
Pollard Elizabeth Ann Hutt
16 Jul 15
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 6.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Private Ocean | 6.00 | $0.00 |